Small Molecule (API) Development

Pharmacology usually limits the term “small molecule” to a molecule that binds to a particular biological macromolecule and acts as an effector molecule, changing the activity or function of the target molecule. Small molecules have a variety of biological functions or applications, such as cell signaling molecules, drugs, agricultural pesticides and so on. These compounds can be natural (e.g. secondary metabolites) or artificial (e.g. antiviral drugs); they may be beneficial to diseases (e.g. drugs) or harmful (e.g. teratogens and carcinogens). Small molecules can be used as research tools to explore biological functions, as well as pioneers in the development of new therapeutic drugs.

BOC Science brings over years of experience in the small molecule development and manufacturing market, where we have considerable experience with a repertoire of chemical reactions and transformations, including but not limited to:

Our Advantages

• Provides a full range of support analysis services, including LCMS, XRPD, ICPMS, and NMR.
• Validation support services (DOE, QbD).
• 32 ventilation cabinets.
• Multiple reactors, process enhancement.
• World-class risk assessment laboratory.
• Expertise in technology transfer, process development and industrialization.
• GMP and non-GMP kg laboratory manufacturing (10, 20, 25 and 50L scales).
• DOE and QbD techniques are used to evaluate and determine key process parameters.
• Research on route reconnaissance and concept demonstration.
• Process development, optimization and industrialization.
• 10L and 20L small cGMP hydrogenation units.

In cooperation with us, you can also seamlessly coordinate the development and production of your small molecular APIs and finished drugs. Our API development services can be combined with our complete family of drug product services, including pre-prescription screening, clinical development and commercial supply-both of which we are world leaders in. Large or small, at each stage, you will gain the advantage of seamless collaboration between our sites, teams, and operations.

References:

1. Chaplin, D. J., Horsman, M. R., & Siemann, D. W. (2006). Current development status of small-molecule vascular disrupting agents. Current opinion in investigational drugs (London, England: 2000), 7(6), 522-528.
2. Woodley, J. M. (2018). Innovative process development and production concepts for small-molecule API manufacturing. Computer Aided Chemical Engineering, 41, 67-84.